The research team, led by investigators studying the genetic landscape of aneurysm tissue, began with a large-scale bioinformatics sweep. They pooled gene expression data from three public datasets of human aortic tissue, comparing aneurysm samples with healthy controls. Principal component analysis showed that the two groups separated cleanly by their gene expression profiles, and differential expression analysis identified 617 genes that were upregulated and 711 genes that were downregulated in aneurysmal tissue. To make sense of this flood of data, the researchers applied weighted gene co-expression network analysis, which clusters genes that move together across samples. Of 32 modules identified, one dark-gray module containing 1,659 genes showed the strongest correlation with aneurysm status and became the focus of further analysis.

The team then intersected this module with two curated gene sets that they suspected might matter in aneurysm biology. The first contained mitochondrial-related genes drawn from the Human MitoCarta3.0 database, capturing proteins involved in oxidative phosphorylation and mitochondrial maintenance. The second captured genes linked to PANoptosis, a recently described form of programmed cell death that combines features of apoptosis, pyroptosis, and necroptosis and is tightly intertwined with inflammatory signaling. This cross-referencing yielded 11 mitochondrial differentially expressed genes and 10 PANoptosis-related differentially expressed genes associated with the disease. Three machine-learning algorithms, LASSO logistic regression, support vector machine recursive feature elimination, and random forest, were then used in parallel to whittle these lists down to a handful of candidate key genes, a strategy designed to reduce the bias that any single algorithm can introduce.

Seven genes survived the full gauntlet of filters: MTHFD2, NDUFAF2, ACADVL, and GLRX5 on the mitochondrial side, and CCT5, RPS27A, and PELI1 on the PANoptosis side. When the researchers measured these candidates in the laboratory, one stood out dramatically. NDUFAF2, short for NADH dehydrogenase ubiquinone 1 alpha subcomplex assembly factor 2, showed the largest expression increase during aneurysm development. The elevation was confirmed at the protein level by immunofluorescence and western blotting in cells treated with angiotensin II, a hormone-like peptide long used to model aneurysm biology, and again in the aortic tissue of aneurysm mice by quantitative PCR and immunohistochemistry. NDUFAF2 is not an obscure player: it serves as an assembly factor for mitochondrial complex I, the first and largest enzyme of the respiratory chain, and mutations in its gene are known to cause severe mitochondrial disease in humans.

To test whether NDUFAF2 was merely a bystander or an active participant, the researchers silenced it with small interfering RNA in mouse vascular smooth muscle cells exposed to angiotensin II. The results were striking. Cells lacking NDUFAF2 proliferated at a significantly higher rate and died at a significantly lower rate than controls. Flow cytometry revealed a sharp drop in apoptosis, and the molecular signature of cell death shifted accordingly: the anti-apoptotic protein Bcl-2 rose, while the pro-apoptotic proteins Bax and cleaved caspase-3 fell. Angiotensin II also crippled the migratory capacity of smooth muscle cells, an effect that NDUFAF2 knockdown largely reversed. Because the loss and dysfunction of vascular smooth muscle cells is considered a central event in aneurysm formation, these findings positioned NDUFAF2 as a plausible mechanistic link between mitochondrial stress and wall weakening.

The next question was how NDUFAF2 exerts this influence, and the answer lay in the mitochondria themselves. MitoTracker staining showed that angiotensin II drastically reduced mitochondrial mass in smooth muscle cells, and transmission electron microscopy revealed swollen organelles with fragmented cristae, the folded inner membranes where energy production takes place. Silencing NDUFAF2 reversed both changes. The protein also rebalanced mitochondrial dynamics, the constant process of fission and fusion that keeps these organelles healthy. Angiotensin II increased DRP1, a fission protein whose overactivity fragments mitochondria, while suppressing OPA1, a fusion protein of the inner membrane that maintains cristae structure and cell survival. NDUFAF2 knockdown lowered DRP1 and restored OPA1, and overexpressing OPA1 in rescue experiments further protected mitochondrial mass, membrane potential, and respiratory function, confirming that OPA1 sits downstream in this protective pathway.

Measurements of mitochondrial respiration told a consistent story. Using a Seahorse analyzer to track the oxygen consumption rate, the researchers found that angiotensin II depressed both basal and maximal respiration, indicating impaired oxidative phosphorylation, and that NDUFAF2 knockdown partially restored these values. Damaged mitochondria are a major source of reactive oxygen species, and MitoSOX staining confirmed that silencing NDUFAF2 significantly reduced mitochondrial superoxide production. This matters because excess mitochondrial ROS does more than damage lipids, proteins, and DNA; it can activate NLRP3 inflammasomes, fuel the release of pro-inflammatory cytokines such as interleukin-1 beta, and amplify the chronic inflammation and matrix degradation that characterize the aneurysmal wall. The same protective pattern held in human aortic smooth muscle cells, where NDUFAF2 knockdown reduced ROS, restored DRP1 and OPA1 balance, improved respiration, and lowered apoptotic rates.

The decisive test came in living animals. The researchers induced aneurysms in male C57BL/6J mice by applying calcium chloride solution to the abdominal aorta, a widely used model of rapid aneurysmal dilation, and delivered anti-NDUFAF2 siRNA by tail vein injection. Four weeks later, the aortas of treated mice were measurably healthier. Abdominal aortic diameters were significantly smaller than in untreated aneurysm controls, hematoxylin and eosin staining showed improved tissue architecture, and elastic fiber staining revealed markedly less degradation of elastin, the resilient protein that gives the aortic wall its recoil. TUNEL assays confirmed that cell death in the vessel wall had dropped, and western blots of aortic tissue showed the same molecular shifts seen in culture: less DRP1, Bax, and cleaved caspase-3, and more OPA1 and Bcl-2. Immunofluorescence for TOM20, a mitochondrial outer membrane marker, and alpha-SMA, a smooth muscle marker, showed that both mitochondrial content and smooth muscle cell preservation were restored, as were the electron transport chain subunits SDHA and SDHB and the contractile marker SM22alpha.

The study’s authors are careful about its boundaries. Their in vivo work relied on a single aneurysm model and only male animals, so the findings will need validation in angiotensin II perfusion models and in both sexes. The precise mechanism by which NDUFAF2 regulates mitochondrial function also remains to be worked out in depth. Even so, the work delivers a conceptually important message: a complex I assembly factor, previously studied mainly in the context of neurodegenerative mitochondrial disease and cancer prognosis, acts as a driver of vascular smooth muscle cell death in aneurysm disease. The finding resonates with earlier reports that mitochondrial NAD+ deficiency impairs type III collagen turnover and triggers aortic aneurysms, tying mitochondrial metabolism to the structural integrity of the vessel wall. If future work confirms that pharmacologically restraining NDUFAF2, or bolstering OPA1-mediated mitochondrial fusion, can stabilize the aortic wall in humans, the silent killer that is abdominal aortic aneurysm may finally acquire a molecular target for prevention and therapy.

Subject of Research: The role of the mitochondrial complex I assembly factor NDUFAF2 in abdominal aortic aneurysm formation through mitochondrial dysfunction-induced vascular smooth muscle cell apoptosis

Article Title: NDUFAF2 promotes abdominal aortic aneurysm formation through mitochondrial dysfunction-induced apoptosis

Article References: He, H., Peng, J., Chen, H., Zhang, Y., Zhan, S., Chen, L., Han, X., & Yin, H. (2026). NDUFAF2 promotes abdominal aortic aneurysm formation through mitochondrial dysfunction-induced apoptosis. iScience, 29(10), Article 115837. https://doi.org/10.1016/j.isci.2026.115837

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.115837

Keywords: abdominal aortic aneurysm, NDUFAF2, mitochondrial dysfunction, apoptosis, vascular smooth muscle cells, OPA1, DRP1, reactive oxygen species, PANoptosis, complex I assembly, elastin degradation, calcium chloride mouse model

Abdominal aortic aneurysms, or AAAs, develop when the wall of the aorta in the abdomen weakens and balloons outward. They are notoriously stealthy: most people carry one without symptoms until it grows large enough to press on surrounding tissue or, catastrophically, ruptures. Ruptured AAAs carry high mortality, and even in settings with rapid surgical response, survival is far from guaranteed. Because the condition is usually asymptomatic in its early stages, identifying modifiable risk factors is one of the most important public health levers available. Elevated mean blood pressure has long been recognized as a contributor, but the new study argues that traditional measures inadequately capture the true hemodynamic stress imposed on the arterial wall.

The research team, led by Ziqin Cao and Qiong Huang of Central South University’s Second Xiangya Hospital together with colleagues, analyzed data from 189,770 UK Biobank participants who had at least three systolic blood pressure measurements linked to primary care records. Rather than relying on a single snapshot, the investigators calculated variability across repeated visits, using multiple statistical metrics to quantify how much each person’s readings fluctuated over time. They then followed the cohort for a median of 10.7 years, during which 1,036 participants developed an incident abdominal aortic aneurysm. Cox proportional hazards models allowed the team to estimate aneurysm risk while adjusting for a battery of cardiovascular risk factors and, crucially, for mean systolic blood pressure itself.

The results were striking in their consistency. Across every variability metric examined, higher systolic blood pressure variability was associated with increased aneurysm risk, with trend tests reaching statistical significance at P values of 0.003 or lower. When the researchers compared participants in the highest tertile of variability with those in the lowest, they found a 33 to 54 percent increase in risk, depending on the metric used. Dose-response analyses suggested the relationship was approximately linear, meaning that each incremental increase in fluctuation corresponded to a proportionally greater hazard, without any apparent threshold effect. Sensitivity analyses designed to probe the robustness of the association—including adjustments for antihypertensive medication use and other potential confounders—left the core finding intact.

Perhaps the most clinically provocative result concerns people whose average blood pressure looks reassuringly normal. Even among participants whose mean systolic pressure remained below 130 mmHg—a level generally considered well controlled under contemporary guidelines—high visit-to-visit variability still conferred elevated aneurysm risk. This suggests that a patient can tick the box for adequate blood pressure control on paper while still experiencing mechanical stresses that may insidiously damage the aortic wall. The biological rationale is plausible: the aorta is an elastic conduit that expands and recoils with every heartbeat, and repeated cycles of stretch and relaxation at varying amplitudes may accelerate degradation of elastin and collagen in the vessel wall, promote inflammation, and foster the endothelial dysfunction that experimental studies have implicated in aneurysm formation.

The study went beyond epidemiology by layering on genomic and proteomic profiling, an approach that reflects a broader movement in cardiovascular research toward multi-omics risk stratification. Using polygenic risk scores, the team stratified participants by inherited susceptibility to abdominal aortic aneurysm. The interaction was dramatic: individuals with both high blood pressure variability and high genetic risk faced more than a two-fold increase in aneurysm incidence, with hazard ratios ranging from 2.07 to 2.28 and P values below 0.001. In other words, genes and hemodynamic turbulence did not merely add together—they appeared to amplify one another, echoing a growing literature showing that genetic predisposition can accentuate the harm of modifiable exposures across conditions from fatty liver disease to obesity-related illness.

To probe the molecular pathways that might connect fluctuating pressure to aneurysm development, the researchers turned to proteomics, measuring circulating proteins and conducting exploratory analyses of indirect effects. Ten proteins showed statistically significant indirect associations after controlling the false discovery rate, with descriptive coefficient-attenuation estimates ranging from 6.7 to 30.4 percent. The authors are careful to frame these findings appropriately: the protein-specific estimates are non-additive and do not establish causal mediation. Still, the identification of candidate circulating proteins offers a molecular bridge between a hemodynamic exposure and a structural vascular disease, and it aligns with recent proteome-wide studies that have nominated inflammatory and lipid-related pathways as central to aneurysm biology.

The study’s strengths are considerable. Its prospective design means blood pressure variability was measured before aneurysms developed, reducing the risk of reverse causation. The sheer scale of the UK Biobank, combined with linked primary care records, provided the repeated measurements needed to compute variability reliably—something smaller cohorts cannot do. The adjustment for mean systolic pressure is particularly important, because variability and average pressure are correlated, and an apparent variability effect could otherwise simply reflect underlying hypertension. By demonstrating that the association persists after accounting for the average, the analysis makes a credible case that variability carries independent information.

Yet the authors and the data itself impose clear limits on interpretation. An observational cohort, however large and well adjusted, cannot prove that smoothing out blood pressure swings would prevent aneurysms. Residual confounding by factors such as medication adherence, measurement error, or underlying illness remains possible, and the exploratory proteomic findings require replication. The researchers explicitly state that their results support systolic blood pressure variability as a potential risk marker and warrant external validation in other populations, but do not establish that reducing variability would avert the disease. That caveat matters, because variability can reflect many things—from genuine hemodynamic lability to inconsistent measurement conditions or irregular medication taking—and interventions targeting it have not been tested for aneurysm prevention.

Even with those qualifications, the study is likely to resonate widely, both in clinics and among the public. It reframes a familiar vital sign as a dynamic signal, hinting that the quiet patient with borderline readings and erratic follow-up measurements may be anything but low risk. It dovetails with prior work linking blood pressure variability to cardiovascular events, chronic kidney disease, dementia, and death, and it complements emerging efforts to build polygenic risk scores and proteomic panels into aneurysm screening programs. For now, the practical message is one of heightened vigilance rather than new prescriptions: clinicians may want to pay closer attention to the consistency of blood pressure control in genetically susceptible patients, and researchers now have a concrete, testable hypothesis about how mechanical stress and inherited vulnerability conspire to weaken the aorta. As with many advances in precision medicine, the swing of the pendulum—in this case, quite literally the swing of a blood pressure reading—may prove as informative as its resting position.

Subject of Research: The association between visit-to-visit systolic blood pressure variability and abdominal aortic aneurysm risk, examined with genomic and proteomic profiling.

Article Title: Systolic blood pressure variability as a risk factor for abdominal aortic aneurysm: a prospective cohort study with genomic and proteomic profiling

Article References: Cao, Z., Huang, Q., Zeng, Y., Nan, W., Li, Y., He, B., Chai, X., & Peng, Z. (2026). Systolic blood pressure variability as a risk factor for abdominal aortic aneurysm: a prospective cohort study with genomic and proteomic profiling. European Journal of Epidemiology. https://doi.org/10.1007/s10654-026-01459-2

Image Credits: AI Generated

DOI: 10.1007/s10654-026-01459-2

Keywords: blood pressure variability, abdominal aortic aneurysm, hypertension, UK Biobank, polygenic risk score, proteomics, cardiovascular disease, aortic wall, risk factors, epidemiology, genetic susceptibility, aneurysm prevention

The study, published in Cellular and Molecular Life Sciences, tested empagliflozin, a sodium-glucose cotransporter 2 inhibitor, in a well-established animal model of aneurysm disease. Male ApoE-deficient mice, which are highly susceptible to vascular pathology, were infused with angiotensin II to trigger abdominal aortic aneurysm formation. One group of animals received the drug at a dose of 3 milligrams per kilogram per day for 28 days. The differences at the end of the study were striking. Among the aneurysm animals, 73.3 percent developed the disease; among those treated with empagliflozin, only 26.6 percent did. Maximum aortic diameter was significantly reduced, aortic rupture became far less common, and survival improved from 73.3 percent to 86.7 percent, a difference the authors report as statistically significant.

Abdominal aortic aneurysm is a permanent, irreversible dilation of the aorta that grows silently over years and can rupture without warning. Rupture carries mortality rates that exceed 80 percent in many settings, and because no drug is currently approved to slow or prevent the disease, the only definitive treatment is surgical repair, typically once the vessel exceeds a critical diameter. The search for a medical therapy has been one of the most persistent unmet needs in vascular medicine, which is why the idea that a glucose-lowering agent might double as an aneurysm-protective drug has generated considerable interest.

What makes the new findings remarkable is not only the magnitude of protection but the mechanism the investigators uncovered. Empagliflozin was already known to deliver cardiovascular benefits beyond its glucose-lowering effects, but this study is among the first to show that its protective activity in aneurysm disease depends on the gut microbiome. When the researchers depleted the animals’ gut bacteria with antibiotics, the drug lost virtually all of its aneurysm-fighting power. Conversely, when they transplanted fecal microbes from empagliflozin-treated mice into untreated animals, the recipients gained the drug’s benefits, showing reduced aneurysm incidence, diminished vascular inflammation, and stronger intestinal barriers. In effect, the microbiome was both necessary and sufficient to transfer the protection.

To understand how a diabetes drug reshapes microbial communities, the team performed 16S rRNA sequencing on fecal samples from each experimental group. The sequencing revealed a clear restructuring of the gut ecosystem. At the phylum level, empagliflozin increased the abundance of Tenericutes, a lesser-known bacterial lineage. At the genus level, the drug enriched several taxa, including Sutterella, Allobaculum, Colinsella, and Pelomonas, while reducing Methylobacterium. Functional prediction analysis using PICRUSt2 suggested shifts in microbial metabolic pathways, indicating that the drug’s influence extended beyond simple taxonomic changes to the biochemical work performed by the community as a whole.

Metabolic readouts confirmed those structural shifts. Targeted liquid chromatography coupled to tandem mass spectrometry showed empagliflozin-associated changes in fecal short-chain fatty acids, the beneficial microbial metabolites that nourish the gut lining and dampen systemic inflammation, as well as changes in plasma trimethylamine N-oxide, a metabolite produced by gut bacteria that has been repeatedly linked to cardiovascular disease. The drug simultaneously raised protective metabolites and lowered harmful ones, tilting the gut’s chemical output in a direction associated with vascular health.

The vascular consequences were equally measurable. In the aortic tissue of aneurysm animals, empagliflozin reduced the infiltration of inflammatory cells, preserved the integrity of elastic fibers in the vessel’s medial layer, and suppressed the angiotensin II-driven upregulation of matrix metalloproteinases, the tissue-destroying enzymes that digest the aortic wall. Levels of MMP9 and MMP2, both central players in aneurysm development, were significantly lower in treated animals. These enzymes are the molecular scissors that progressively weaken the artery; restraining them is widely considered the key pharmacological goal in aneurysm research.

The gut side of the story proved just as important. Aneurysm-inducing angiotensin II damages the intestinal barrier, allowing bacterial products such as lipopolysaccharide to leak into the bloodstream and inflame distant organs, including the aorta. Empagliflozin reversed this damage. Treated mice showed restored intestinal villus structure, upregulated expression of the tight-junction proteins ZO-1 and Occludin at both the mRNA and protein levels, reduced intestinal permeability, and markedly lower plasma lipopolysaccharide concentrations. Downstream in the aortic wall, the drug attenuated TLR4/NF-κB signaling, the classical inflammatory pathway activated by bacterial products that drives the chronic inflammation underlying aneurysm growth.

Assembled together, the evidence outlines a coherent biological circuit. Empagliflozin reshapes the gut microbiota, enriching beneficial taxa and shifting metabolite production toward short-chain fatty acids. Those changes restore the integrity of the intestinal barrier, preventing bacterial toxins from crossing into the circulation. With fewer circulating toxins, TLR4/NF-κB inflammation in the aortic wall subsides, destructive metalloproteinases are restrained, elastic fibers survive, and the artery remains structurally sound. The antibiotic depletion and fecal transplantation experiments serve as the causal linchpins of this model, demonstrating that the gut microbial community is the mediator through which the drug exerts its vascular protection rather than an incidental bystander.

The findings carry implications that extend well beyond aneurysm research. They suggest that some of the cardiovascular benefits of SGLT-2 inhibitors, a drug class already credited with unexpected heart and kidney protection in large clinical trials, may be mediated in part through the gut. They also point toward microbiome-based strategies for aneurysm prevention, whether through drugs, diet, or microbial therapies, in a disease where medicine currently offers nothing between surveillance and surgery. The authors are careful to frame the work as experimental: the results come from mice given angiotensin II, and human aneurysms develop over decades in a very different physiological context. Clinical trials in patients will be needed to determine whether empagliflozin, or the microbial signatures it promotes, can slow aneurysm growth in people. Still, the study provides a novel preventive strategy and a clear mechanistic target, the gut microbiota and intestinal barrier axis, for a disease that has lacked one. For the millions of patients carrying small, silently enlarging aneurysms, the possibility that a widely available drug might one day stop the growth is a prospect worth watching closely, and the gut, once again, sits at the center of the story.

Subject of Research: Gut microbiome-mediated protective effects of the SGLT-2 inhibitor empagliflozin against experimental abdominal aortic aneurysm formation and progression

Article Title: Gut microbiome mediates the protective effects of empagliflozin on experimental abdominal aortic aneurysm formation and progression

Article References: Guo, W., Hu, H., Wang, S., Li, D., Li, C., Chen, X., Deng, D., Xiao, J., Shen, Y., & Wei, Z. (2026). Gut microbiome mediates the protective effects of empagliflozin on experimental abdominal aortic aneurysm formation and progression. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06449-x

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06449-x

Keywords: abdominal aortic aneurysm, empagliflozin, SGLT-2 inhibitor, gut microbiota, intestinal barrier, inflammation, 16S rRNA sequencing, short-chain fatty acids, TMAO, TLR4/NF-κB signaling, MMP9, fecal microbiota transplantation

The research team, led by Katharina Alina Riedl of the University Medical Center Hamburg-Eppendorf and collaborators at institutions including Charité Berlin and the German Centre of Cardiovascular Research, analyzed data from 2,093 participants who had undergone both advanced magnetic resonance imaging of the heart and aorta and a dedicated ultrasound examination of the abdominal aorta. The participants, drawn from the first 10,000 volunteers enrolled in the Hamburg City Health Study between February 2016 and November 2018, had a median age of 66 years, and roughly 42 percent were women. The Hamburg City Health Study is an ambitious, single-center, prospective epidemiological project aiming to follow more than 20,000 residents of Hamburg aged 45 to 74 over the long term, making it an ideal laboratory for studying how vascular aging manifests in a general population rather than in selected patient groups.

At the heart of the study are two measurements that cardiologists describe as windows into the biological age of the arteries. The first is pulse wave velocity, or PWV, which quantifies how fast the pressure wave generated by each heartbeat travels along the aortic wall. A stiffer artery propagates the wave more quickly, so higher PWV signals greater arterial stiffness, itself both a contributor to and a consequence of atherosclerosis and vascular aging. The second is aortic distensibility, or AD, which captures how much the aortic wall expands with each pulse of blood; a healthy, elastic aorta distends readily, whereas a stiffened vessel barely moves. Both parameters were derived from two-dimensional phase-contrast velocity-encoded CMR sequences acquired on a 3 Tesla scanner, with regions of interest placed manually in the ascending and descending aorta and then automatically propagated through the cardiac cycle.

The technical approach matters, because measuring aortic stiffness is notoriously method-sensitive. The team computed PWV as the distance between two measurement points divided by the transit time of the pulse wave, with the distance determined precisely by tracing an aortic centerline on a parasagittal T2-weighted HASTE image rather than estimating it from surface landmarks. The transit time was determined using the PWV 50 percent algorithm, which identifies the moment flow reaches half of its peak in each aortic segment, a method chosen because prior work showed it delivers the highest reproducibility with the fewest outliers. Distensibility, in turn, was calculated as the relative change in aortic diameter over the cardiac cycle divided by the pulse pressure measured at the brachial artery. This centerline-based CMR approach stands in contrast to the conventional carotid-femoral PWV technique, which relies on approximate surface distances and, the authors argue, may be unreliable in people with enlarged abdominal aortas because it samples a different vascular territory.

The ultrasound side of the investigation focused on the infrarenal aorta, the segment below the renal arteries where the overwhelming majority of abdominal aortic aneurysms arise. Using a convex array transducer, sonographers measured the maximum anteroposterior diameter in systole with the outer-to-outer method, as well as the peak flow velocity of blood moving through the vessel. Following current European clinical practice guidelines, a diameter between 25 and 29 millimeters was classified as ectasia and a diameter of 30 millimeters or more as an aneurysm. The median diameter in the cohort was 18.1 millimeters and the median peak flow velocity was 98.6 centimeters per second. In total, 55 participants had either ectasia or an aneurysm, including 21 with a true aneurysm, a prevalence consistent with earlier reports from the same cohort.

The statistical analysis, performed with linear and logistic regression models adjusted progressively for age, sex, and classical cardiovascular risk factors including hypertension, hyperlipidemia, diabetes, smoking, and body mass index, produced a nuanced picture. After adjustment for age and sex, the maximum infrarenal aortic diameter was significantly associated with the distensibility of the descending thoracic aorta, with a regression coefficient of −0.572 and a p-value of 0.009, meaning that people whose descending aorta distends less also tend to have wider infrarenal segments. Likewise, peak flow velocity in the infrarenal aorta was significantly associated with pulse wave velocity, with a coefficient of −0.399 and a p-value of 0.029, indicating that faster aortic pulse waves travel alongside slower peak flow in the abdominal vessel. Adding these stiffness parameters to models containing only age and sex significantly improved model fit in both cases, as confirmed by likelihood ratio tests.

Perhaps the most striking findings emerged when the researchers compared participants with ectasia or aneurysm against those with normal aortic diameters. The 55 affected individuals had significantly higher median pulse wave velocity, 8.59 versus 7.58 meters per second, alongside significantly lower distensibility in both the ascending and descending aorta and significantly lower peak flow velocity, 84.30 versus 98.70 centimeters per second. They also carried a heavier burden of cardiovascular risk factors, with significantly higher rates of hypertension, hyperlipidemia, smoking, prior myocardial infarction, and elevated body mass index. Yet when the same stiffness parameters were tested as predictors of prevalent ectasia or aneurysm in adjusted logistic regression models, none retained a statistically significant predictive value. The differences were real but modest in absolute terms, and the small number of affected participants, particularly the few women in this subgroup, limited statistical power.

This apparent paradox, significant group differences but no individual-level predictive power, carries an important message for the field. The authors conclude that CMR-based aortic stiffness parameters are associated with infrarenal aortic geometry and flow, but that their diagnostic, screening, and prognostic value remains to be established. Screening for abdominal aortic aneurysm currently rests on simple ultrasound diameter thresholds, and the new data suggest that thoracic stiffness measurements are unlikely to replace that approach. However, the findings leave open the possibility that pulse wave velocity and distensibility could help identify individuals at risk of future aneurysm development or rupture vulnerability, questions that the ongoing follow-up of the Hamburg cohort is designed to address. The biology reinforces this caution: the infrarenal aorta has a lower elastin-to-collagen ratio than the thoracic aorta, so stiffness in one segment does not simply mirror stiffness in the other.

The study is not without limitations, which the authors acknowledge candidly. It was conducted at a single center, the cohort contained far more men than women, and only 21 participants had a true aneurysm, an expected figure given the population-based design and the known prevalence of roughly 0.8 percent in this cohort. Peak flow velocity may also be confounded by the cross-sectional area of the vessel, since a larger lumen mechanically reduces peak velocity regardless of wall stiffness. The team used two-dimensional flow CMR rather than the more information-rich four-dimensional technique, a deliberate trade-off favoring fast acquisition and feasibility in large population studies, and brachial blood pressure served as a surrogate for central aortic pressure in the distensibility calculation. Nonetheless, by combining magnetic resonance and ultrasound data in the same large, unselected sample, the study represents the largest investigation to date linking CMR-derived aortic stiffness with ultrasound-based infrarenal parameters, and it sets the stage for longitudinal analyses that may finally determine whether the stiffness of the great vessels can foretell the vessels’ most dangerous failure mode.

Subject of Research: Associations between CMR-based aortic stiffness parameters and ultrasound-based infrarenal aortic parameters in a population-based cohort

Article Title: Associations of CMR-based pulse wave velocity and aortic distensibility with infrarenal ultrasound-based aortic parameters in the Hamburg City Health Study

Article References: Riedl, K. A., Di Carluccio, E., Lund, G., Huellebrand, M., Hennemuth, A., Braren, R., Kirchhof, P., Blankenberg, S., Tilemann, L., Ziegler, A., Behrendt, C. A., Muellerleile, K., & Kölbel, T. (2026). Associations of CMR-based pulse wave velocity and aortic distensibility with infrarenal ultrasound-based aortic parameters in the Hamburg City Health Study. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03029-8

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03029-8

Keywords: pulse wave velocity, aortic distensibility, aortic stiffness, abdominal aortic aneurysm, cardiovascular magnetic resonance, infrarenal aorta, ultrasound, Hamburg City Health Study, arterial stiffening, vascular aging, aneurysm screening, cardiovascular risk factors